洪玉清(湖北省公安县中医医院药剂科，湖北 荆州　434300)



丹参多酚酸盐与丹参酮ⅡA磺酸钠注射液治疗冠心病心绞痛的疗效及药物经济学比较

洪玉清*(湖北省公安县中医医院药剂科，湖北 荆州434300)

DOI10.14009/j.issn.1672-2124.2016.03.008

摘要目的：探讨丹参多酚酸盐与丹参酮 ⅡA磺酸钠注射液治疗冠心病心绞痛的疗效及药物经济学差异。方法：选取公安县中医医院2011年5月—2014年7月收治的冠心病心绞痛患者188例，按随机数字表法分成2组各94例。对照组患者给予丹参酮ⅡA磺酸钠注射液，观察组给予注射用丹参多酚酸盐，比较2组患者临床疗效及不良反应发生情况，记录两种药物日均成本和疗程成本的差异。结果：观察组患者总有效率为94.68%(89/94)，高于对照组的77.66%(73/94)，差异有统计学意义(P<0.05)；观察组患者出现眩晕2例(2.13%)，头痛2例(2.13%)，血丙氨酸转氨酶升高1例(1.06%)，与对照组的1例(1.06%)，1例(1.06%)，1例(1.06%)比较，差异无统计学意义(P>0.05)；观察组患者日均成本为(184.30±5.50)元，疗程成本为(2 576.90±26.30)元，高于对照组的(19.30±1.30)、(273.60±3.80)元，差异有统计学意义(P<0.05)。结论：注射用丹参多酚酸盐静脉滴注方案治疗冠心病心绞痛临床疗效较丹参酮 ⅡA磺酸钠注射液突出，但丹参酮 ⅡA磺酸钠注射液经济性较强，医师在临床用药时应当充分考虑患者病情发展程度及实际经济条件，选择最佳用药方案。

关键词丹参多酚酸盐； 丹参酮ⅡA磺酸钠注射液； 冠心病心绞痛； 药物经济学

Pharmacoeconomic Comparison and Efficacy Observation on Salvianolate and Tanshinone ⅡASulfonic Acid Natrium Injection in Treatment of Angina Pectoris of Coronary Heart Disease

HONG Yuqing(Dept.of Pharmacy, Gong’an County Traditional Chinese Medicine Hospital, Hubei Jingzhou 434300, China)

ABSTRACTOBJECTIVE：To probe into the pharmacoeconomic difference and efficacy of salvianolate and tanshinone ⅡAsulfonic acid natrium injection in treatment of angina pectoris of coronary heart disease(CHD). METHODS: 188 cases with angina pectoris of CHD admitted into Hubei Gong’an County Traditional Chinese Medicine Hospital from May 2011 to Jul. 2014 were selected to be divided into two group via the random number table, with 94 cases in each. The control group were treated with intravenous tanshinone ⅡAsulfonic acid natrium injection, while the observation group received intravenous infusion therapy of salvianolate. After treatment, the clinical efficacy and incidence of adverse drug reactions in two group of patients were compared. Differences of daily cost and cost of a treatment course of the two kinds of drugs were recorded. RESULTS: The total efficiency of the observation group was 94.68%(89/94), higher than that of control group 77.66%(73/94), the difference was statistically significant(P<0.05). In observation group, there were 2 cases of megrim(2.13%), 2 cases of headache(2.13%) and 1 case with the increase of serum glutamic pyruvic transaminase(1.06%); and compared with the control group, respectively 1 case (1.06%), 1 case (1.06%) and 1 case (1.06%), the difference was not statistically significant(P>0.05). The daily cost and cost of a treatment course of observation group were (184.30±5.50) yuan and (2 576.90±26.30) yuan, higher than that of control group (19.30±1.30) yuan and (273.60±3.80) yuan, with statistically significant difference (P<0.05). CONCLUSIONS: The clinical efficacy of intravenous infusion of salvianolate injection is more prominent than that of tanshinone IIAsulfonate injection, but the economy of tanshinone IIAsulfonate sodium injection is stronger. Meanwhile, the physicians should fully consider the degree of disease progression and the actual economic conditions of patients in clinical medication, so as to choose the best treatment scheme.

KEYWORDSSalvianolate; Tanshinone IIAsulfonate injection; Angina pectoris of coronary heart disease; Pharmacoeconomics

冠心病心绞痛是一种以发作性胸痛为主要表现的临床常见综合征，全球每年发病患者占世界总人口的1.40%～1.60%[1]，现已成为威胁人类生命健康安全的首位疾病。据不完全调查结果显示，该病在我国发病率呈逐年递增及年轻化趋势[2]。祖国医学将其归入“胸痹心痛”范畴，认为其发病同七情内伤、寒邪侵体等因素相关。丹参是一种具有活血通络、祛瘀止痛、清心除烦等功效的中药材，生物学活性广泛[3]，被应用于多种治疗心血管疾病的中成药方剂配伍中，其临床疗效已获得广泛肯定。本研究观察了丹参多酚酸盐与丹参酮ⅡA磺酸钠注射液治疗冠心病心绞痛的临床疗效及药物经济学差异，现报告如下。……